Open Nav

Applying Artificial Intelligence to Improve Therapy Development Today

  • Gini Deshpande, NuMedii, Inc.,
  • Parvez Ahammad , BlackThorn Therapeutics,
  • Josep Bassaganya-Riera, Landos Biopharma,
  • Jeffrey Brewer, Bigfoot Biomedical,
  • Alex Morgan , Khosla Ventures ,
  • Edward Painter, A2A Pharmaceuticals

As new techniques in artificial intelligence expand the functionality of software to find useful results from large data sets, progress companies are already folding such tools into their developments of new therapies to address unmet needs of patients. For example, companies are using the “always-on” power of computers to filter existing molecular libraries and model new drug discovery techniques in ways never before possible. This session will feature experts working at the intersection of information technology, therapy delivery, and new drug development, who can show the exponential power of machine learning and other artificial intelligence approaches to turn data into medicine.

Moderator: Gini Deshpande, PhD, Founder & Chief Executive Officer, NuMedii

  • Date:Thursday, October 18
  • Time:2:45 PM - 3:55 PM
  • Session Type:Educational Session
Gini Deshpande
NuMedii, Inc.
Parvez Ahammad
BlackThorn Therapeutics
Josep Bassaganya-Riera
Landos Biopharma
Jeffrey Brewer
Bigfoot Biomedical
Alex Morgan
Khosla Ventures
Edward Painter
A2A Pharmaceuticals